Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-122837
Abstract: Background: A myeloproliferative neoplasm (MPN) is frequent underlying cause of splanchnic vein thrombosis (SVT). We reported that ruxolitinib, a JAK1/2 inhibitor, was safe in patients (pts) with MPN-associated SVT and effective in reducing spleen size… read more here.
Keywords: reduction; response; analysis; mpn associated ... See more keywords
A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps7083
Abstract: TPS7083Background: Anemia is an important complication of MPN-associated myelofibrosis. There are few effective therapies other than RBC transfusions, and responses to other therapies are typically... read more here.
Keywords: associated myelofibrosis; phase multicenter; anemia; mpn associated ... See more keywords